Drugs / B002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04382352 | May 2019 → Apr 2022 | breast carcinoma | Shanghai Pharmaceuticals Holding Co., Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04382352 ↗ |
| Modality | Monoclonal antibody | “humanized monoclonal antibody composition” NCT04382352 ↗ |
| Route | Intravenous | “Usage: intravenous infusion” NCT04382352 ↗ |
| Target | ERBB2 | “anti-HER2 humanized monoclonal antibody composition” NCT04382352 ↗ |